tbuckley/cabot-search huggingface dataset:
Surgeon is suspended for 12 months after working at private hospital while suspended from NHS
Authors: Clare Dyer
Journal: BMJ (2021)

A consultant orthopaedic surgeon has been suspended from the UK medical register for 12 months after working at a private hospital when suspended from his NHS job and while on sick leave. Simon Thomas was told that he had narrowly escaped erasure for performing procedures that he had been told to stop doing.

Thomas had restrictions imposed on his practice in hand and wrist surgery by NHS Tayside in June 2018 after he had incorrectly removed a patient’s median nerve believing it to be a tendon. But he failed to notify the two private hospitals where he worked of …
AB0353 ADRENAL INSUFFICIENCY AFTER GLUCOCORTICOID TREATMENT OF GIANT CELL ARTERITIS
Authors: A. Hočevar, R. Jese, J. Kramarič, M. Tomsic, Z. Rotar
Journal: Annals of the Rheumatic Diseases (2021)

Background: Adrenal insufficiency is frequently neglected and underappreciated, potentially severe complication of systemic glucocorticoid therapy. Objectives: We aimed to evaluate the prevalence of glucocorticoid induced adrenal insufficiency in giant cell arteritis (GCA). Methods: We analysed adrenal function data in a cohort of GCA patients diagnosed between July 2014 and July 2019, in whom discontinuation of methylprednisolone therapy was planned. Adrenal function was tested by Corticotropin stimulation test (CST). To perform the CST, methylprednisolone was substituted with hydrocortisone (20mg qd in three divided doses) for one to four weeks before the test. Adrenal insufficiency was defined as cortisol level &lt;450 nmol/l measured 30 minutes after the corticotropin injection; additionally, the result of the CST was defined as borderline when the cortisol level 30 minutes after corticotropin injection was between 450 nmol/l and 500 nmol/l. Results: Adrenal function was tested in 74/215 GCA patients before definite methylprednisolone withdrawal (after a median 13.5 (12.9 – 22.4) months of glucocorticoid therapy). The mean (SD) methylprednisolone dose, prior to substitution with hydrocortisone and subsequent CST, was 3.1 (1.6) mg. Adrenal insufficiency was detected in 36/74 patients (48.6%); additionally, 10/74 patients (13.5%) had a borderline CST result. Seventeen patients with either adrenal insufficiency or borderline CST result, had a repeated CST after median (IQR) 11.6 (8.9; 12.6) months. Adrenal insufficiency persisted in 11/17 (64.7%) patients, and 1/17 patients had a borderline CST. A third CST was performed in 4/12 patients with abnormal second CST after median (IQR) 8.3 (6.9; 10.6) months. Adrenal function recovered in one patient, while the adrenal insufficiency persisted in the remaining 3 patients. Conclusion: Adrenal insufficiency is a common and potentially long-lasting glucocorticoid induced adverse event in GCA patients. Disclosure of Interests: None declared
Community-Based Organizations Step Up to Confront HIV in Southern States
Authors: Bridget M. Kuehn
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
POS0466 RHEUMATOID ARTHRITIS PER SE IS NOT RISK FACTOR FOR CLINICAL FRACTURES: NINE-YEAR FINDINGS OF THE TOMORROW STUDY
Authors: K. Mamoto, T. Koike, Y. Yamada, T. Okano, Y. Sugioka, M. Tada, K. Inui, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2021)

Background: Patients with rheumatoid arthritis (RA) who have sarcopenia and stiff or painful joints might be at increased risk of falls and fractures. Objectives: The present study aimed to prospectively identify the incidence of clinical fractures and associated risk factors in patients with RA in a cohort study named the TOMORROW (UMIN000003876) that started in 2010. Methods: We evaluated anthropometric parameters, bone mineral density (BMD), disease activity, RA medication at baseline and observed the incidence of clinical fractures during nine years in 202 patients with RA (mean age, 58.6 y; medication with biological agents, 54.9%) and 202 age- and sex-matched non-RA volunteers (mean age, 57.4 y). We compared the incidence of clinical fractures between patients with RA and controls for nine years, and analyzed the risk factors for fractures using Cox proportional hazard model. Results: The incidence of clinical fractures in RA patients was significantly higher compared to controls (27.5 vs 18.3%, p=0.04). However, Cox proportional hazard model, adjusted by age, sex, smoking and body mass index, revealed that low BMD at thoracic vertebrae (&lt; 0.7 g/cm 2 ) significantly associated to the incidence of clinical fractures (hazard ratio [HR], 1.86, p=0.02), but not RA morbidity (HR 1.47, p=0.10) (Table 1). Among patients with RA, low BMD at the thoracic vertebrae (&lt; 0.7 g/cm 2 ) was the most prominent risk factor for clinical fractures (HR, 2.66, p=0.02) (Table 1). Although the use of glucocorticoid (GC) at baseline (HR, 1.68, p=0.09) was not a significant risk factor for fractures, a mean GC dose (≥ 2 mg/day) at entry increased risk for clinical fractures in the patients (HR, 1.91, p=0.04) (Table 1). Conclusion: RA per se was not a risk factor for clinical fractures in this cohort. Low BMD at the thoracic vertebrae and the use of GC with even low dose at entry were apparently significant risk factors for the incidence of clinical fractures among patients with RA. Disclosure of Interests: Kenji Mamoto: None declared, Tatsuya Koike Grant/research support from: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, Yutaro Yamada: None declared, Tadashi Okano: None declared, Yuko Sugioka: None declared, Masahiro Tada: None declared, Kentaro Inui Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd., Hiroaki Nakamura: None declared
Industry Payments to Medical Oncologists
Authors: Takanao Hashimoto, Akihiko Ozaki, Tetsuya Tanimoto
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
Authors: Caicun Zhou, Lin Wu, Yun Fan, Zhehai Wang, Lianke Liu, Gongyan Chen, Li Zhang, Dingzhi Huang, Shundong Cang, Zhixiong Yang, Jianying Zhou, Chengzhi Zhou, Baolan Li, Juan Li, Min Fan, Jiuwei Cui, Yuping Li, Hui Zhao, Jian Fang, Jianxin Xue, Chengping Hu, Ping Sun, Yingying Du, Hui Zhou, Shuyan Wang, Wen Zhang
Journal: Journal of Thoracic Oncology (2021)
Flexible Electrodes for In Vivo and In Vitro Electrophysiological Signal Recording
Authors: Mengjia Zhu, Huimin Wang, Shuo Li, Xiaoping Liang, Mingchao Zhang, Xiaochuan Dai, Yingying Zhang
Journal: Advanced Healthcare Materials (2021)

Abstract A variety of electrophysiological signals (electrocardiography, electromyography, electroencephalography, etc.) are generated during the physiological activities of human bodies, which can be collected by electrodes and thus provide critical insights into health status or facilitate fundamental scientific research. The long‐term stable and high‐quality recording of electrophysiological signals is the premise for their further applications, leading to demands for flexible electrodes with similar mechanical modulus and minimized irritation to human bodies. This review summarizes the latest advances in flexible electrodes for the acquisition of various electrophysiological signals. First, the concept of electrophysiological signals and the characteristics of different subcategory signals are introduced. Second, the invasive and noninvasive methods are reviewed for electrophysiological signal recording with a highlight on the design of flexible electrodes, followed by a discussion on their material selection. Subsequently, the applications of the electrophysiological signal acquisition in pathological diagnosis and restoration of body functions are discussed, showing the advantages of flexible electrodes. Finally, the main challenges and opportunities in this field are discussed. It is believed that the further exploration of materials for flexible electrodes and the combination of multidisciplinary technologies will boost the applications of flexible electrodes for medical diagnosis and human–machine interface.
DNA Nanotechnology‐Based Biosensors and Therapeutics
Authors: Luyao Shen, Pengfei Wang, Yonggang Ke
Journal: Advanced Healthcare Materials (2021)

Over the past few decades, DNA nanotechnology engenders a vast variety of programmable nanostructures utilizing Watson-Crick base pairing. Due to their precise engineering, unprecedented programmability, and intrinsic biocompatibility, DNA nanostructures cannot only interact with small molecules, nucleic acids, proteins, viruses, and cancer cells, but also can serve as nanocarriers to deliver different therapeutic agents. Such addressability innate to DNA nanostructures enables their use in various fields of biomedical applications such as biosensors and cancer therapy. This review is begun with a brief introduction of the development of DNA nanotechnology, followed by a summary of recent applications of DNA nanostructures in biosensors and therapeutics. Finally, challenges and opportunities for practical applications of DNA nanotechnology are discussed.
Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis
Authors: Payam Mohassel, Sandra Donkervoort, Museer A. Lone, Matthew Nalls, Kenneth Gable, Sita D. Gupta, A. Reghan Foley, Ying Hu, Jonas Alex Morales Saute, Ana Lucila Moreira, Fernando Kok, Alessandro Introna, Giancarlo Logroscino, Christopher Grunseich, Alec R. Nickolls, Naemeh Pourshafie, Sarah B. Neuhaus, Dimah Saade, Andrea Gangfuß, Heike Kölbel, Zoe Piccus, Claire E. Le Pichon, Chiara Fiorillo, Cindy V. Ly, Ana Töpf, Lauren Brady, Sabine Specht, Aliza Zidell, Helio Pedro, Eric Mittelmann, Florian P. Thomas, Katherine R. Chao, Chamindra G. Konersman, Megan T. Cho, Tracy Brandt, Volker Straub, Anne M. Connolly, Ulrike Schara, Andreas Roos, Mark Tarnopolsky, Ahmet Höke, Robert H. Brown, Chia-Hsueh Lee, Thorsten Hornemann, Teresa M. Dunn, Carsten G. Bönnemann
Journal: Nature Medicine (2021)
Immune Responses to SARS-CoV-2 Among Patients With Cancer
Authors: Lova Sun, Jeremy L. Warner, Ravi B. Parikh
Journal: JAMA Oncology (2021)

Shu Yazaki, MD; Tatsuya Yoshida, MD, PhD; Yuki Kojima, MD, PhD; Shigehiro Yagishita, MD, PhD; Hiroko Nakahama, RN, MA; Keiji Okinaka, MD; Hiromichi Matsushita, MD, PhD; Mika Shiotsuka, MD; Osamu Kobayashi, MD, PhD; Satoshi Iwata, MD, PhD; Yoshitaka Narita, MD, PhD; Akihiro Ohba, MD; Masamichi Takahashi, MD, PhD; Satoru Iwasa, MD, PhD; Kenya Kobayashi, MD, PhD; Yuichiro Ohe, MD, PhD; Tomokazu Yoshida, PhD; Akinobu Hamada, PhD; Toshihiko Doi, MD, PhD; Noboru Yamamoto, MD, PhD
Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results From the FoRtitude Randomized Trial
Authors: Lynne I Wagner, Janet A Tooze, Daniel L Hall, Beverly J Levine, Jennifer Beaumont, Jenna Duffecy, David Victorson, William Gradishar, Joseph Leach, Thomas Saphner, Keren Sturtz, Mary Lou Smith, Frank Penedo, David C Mohr, David Cella
Journal: JNCI Journal of the National Cancer Institute (2021)

Fear of recurrence (FoR) is a prevalent concern among breast cancer survivors (BCS), yet few accessible interventions exist. This study evaluated a targeted eHealth intervention, "FoRtitude," to reduce FoR using cognitive behavioral skills training and telecoaching.BCS (N = 196) were recruited from an academic medical center and 3 National Cancer Institute Community Oncology Research Program community sites, had stage 0-III breast cancer, were 1-10 years postprimary treatment, with moderate to high FoR and familiarity with the internet. Using the Multiphase Optimization Strategy, participants were independently randomly assigned to 3 cognitive behavioral skills (relaxation, cognitive restructuring, worry practice) vs an attention control condition (health management content [HMC]) and to telecoaching (motivational interviewing) vs no telecoaching. Website content was released across 4 weeks and included didactic lessons, interactive tools, and a text-messaging feature. BCS completed the Fear of Cancer Recurrence Inventory at baseline and at 4 and 8 weeks. Fear of Cancer Recurrence Inventory scores over time were compared using mixed-effects models. All statistical tests were 2-sided.FCRI scores [SD] decreased statistically significantly from baseline to postintervention (T0 = 53.1 [17.4], T2 = 41.9 [16.2], P < .001). The magnitude of reduction in FCRI scores was comparable across cognitive behavior therapy (CBT) and attention control HMC conditions and was predicted by increased self-efficacy. Telecoaching was associated with lower attrition and greater website use (mean adherence score [SD] = 26.6 [7.2] vs 21.0 [10.5], P < .001).BCS experienced statistically significant reductions in FoR postintervention, but improvements were comparable between CBT and attention controls. Telecoaching improved adherence and retention. Future research is needed on optimal integration of CBT and HMC, dose, and features of eHealth delivery that contributed to reducing FoR. In the COVID-19 era, remote delivery has become even more essential for reaching survivors struggling with FoR.
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
Authors: Henrik Østergaard, Jacob Lund, Per J. Greisen, Stine Kjellev, Anette Henriksen, Nikolai Lorenzen, Eva Johansson, Gustav Røder, Morten G. Rasch, Laust B. Johnsen, Thomas Egebjerg, Søren Lund, Henrik Rahbek-Nielsen, Prafull S. Gandhi, Kasper Lamberth, Mette Loftager, Lisbeth M. Andersen, Amalie C. Bonde, Fabian Stavenuiter, Daniel E. Madsen, Xun Li, Thomas L. Holm, Carsten D. Ley, Peter Thygesen, Haisun Zhu, Rong Zhou, Karina Thorn, Zhiru Yang, Mette B. Hermit, Jais R. Bjelke, Bjarne G. Hansen, Ida Hilden
Journal: Blood (2021)
Restoring Vaccine Diplomacy
Authors: Peter J. Hotez, K. M. Venkat Narayan
Journal: JAMA (2021)

Govind Persad, JD, PhD; Ezekiel J. Emanuel, MD, PhD; Samantha Sangenito, MPA; Aaron Glickman, MPA; Steven Phillips, MD, MPH; Emily A. Largent, JD, PhD, RN
IFN-α Upregulates the Expression of C/EBPβ and Induces Myeloid Differentiation and Exhaustion of CD34+ CML Stem Cells
Authors: Asumi Yokota, Hideyo Hirai, Atsushi Sato, Naoka Kamio, Yoshihiro Hayashi, Yasuo Miura, Shinya Kimura, Taira Maekawa
Journal: Blood (2017)
POS1019 INCONSISTENCY OF THE DEGREE OF CARDIOVASCULAR RISK WHEN ASSESSED USING DIFFERENT INDICES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Authors: E. Vasilenko, A. Dadalova, R. Samigullina, V. Mazurov
Journal: Annals of the Rheumatic Diseases (2021)

Background: Evaluation of indicators of cardiovascular risk is one of the main tasks facing a rheumatologist in the tactics of choosing a therapy for patients (pts) with axial spondyloarthritis (axSpA). It is known that pts suffering from axSpA are characterized by a significant increase in cardiovascular risk (CVR). However, there are still no recommendations regulating risk assessment scales in pts with axSpA. Objectives: were to assess the CVR in pts with axSpA and to compare different cardiovascular risk scales in these pts. Methods: The study included 55 pts at the age of 45-65 years with diagnosis of axSpA fulfilling ASAS criteria (2009) from St. Petersburg’ axSpA register. Three indices of cardiovascular risk evaluation (Systematic COronary Risk Evaluation (SCORE) with increasing coefficient 1.5 for inflammatory diseases, Reynolds Risk Score (RRS), and the third modification of QRESEARCH Cardiovascular Risk Algorithm (QRISK3) were calculated. Risk gradation: low risk (&lt;1%), medium (1.0-4.9%), high (5.0-9.9%), very high (&gt; 10%). Results: Mean age of the pts was 45.8±10.3 years; males - 37 (67.3%) pts, HLA-B27 positive – 34 (61.8%); mean disease duration 12.5±8.7 years. Mean value of SCORE was 2.83±1.89%, of RRS – 5.04±3.98%, of QRISK3 – 7.91±4.91%. The gradation of the degree of risk depending on the applied assessment index is presented in Table 1. Index Results Risk degree SCORE RRS QRISK3 Low 21 (38,2%) 8 (14,5%) 0 (0,0%) Medium 26 (47,3%) 23 (41,8%) 17 (30,9%) High 8 (14,5%) 17 (30,9%) 22 (40,0%) Very high 0 (0,0%) 7 (12,7%) 16 (29,1%) Particular attention is drawn to the 100% discrepancy of low risk values when comparing SCORE and QRISK3. A similar trend persisted when comparing medium, high and very high risk. Thus, the assessment of the risks of 10-year significant cardiovascular events in pts with axSpA using the SCORE index does not coincide with the QRISK3 index data in 87.27% of cases, and with the RRS data - in 58.18% of cases. In 84.3% of cases, the mismatch between the SCORE and RRS indexes was due to the presence of an increased CRP level. Conclusion: When assessing cardiovascular risk in pts with axial spondyloarthritis, a discrepancy was found between the degrees of risk when assessed using different scales. SCORE scores were significantly different from Reynolds’ and QRISK3 scores. These features can be interrelated with a small number of factors assessed when calculating the SCORE, even though there is a correction factor for rheumatic diseases. For pts with axial spondyloarthritis, it is necessary to use additional indicators that influence cardiovascular risk, such as CRP. Disclosure of Interests: None declared.
Bone Marrow Activation After Chemotherapy Presenting as Diffuse Skeletal Uptake on 18F-Fluorocholine PET/CT
Authors: Silvia Taralli, Fabrizio Cocciolillo, Anna Rita Alitto, Carmelo Caldarella
Journal: Clinical Nuclear Medicine (2021)

Abstract Diffuse 18 F-FDG skeletal uptake due to chemotherapy-induced bone marrow activation is well documented, whereas it has never been reported with 18 F-fluorocholine. We described a patient with pelvic recurrence of prostate cancer at 18 F-fluorocholine PET/CT. A second PET/CT after docetaxel showed minimal residual activity in pelvis, but it revealed diffuse, intense 18 F-fluorocholine skeletal uptake. Considering biochemical and metabolic response and absence of morphologically suspected bone lesions, skeletal hyperactivity was interpreted as chemotherapy-related bone marrow rebound rather than diffuse metastatic involvement, as confirmed by its resolution after treatment ended. The occurrence of such 18 F-fluorocholine pattern should be considered to avoid imaging misinterpretation.
Abstract 13261: Effect of Velocity Profile and Shape of Left Ventricular Outflow Tract on Left Ventricular Stroke Volume Validated Using Echo and 4D Flow MRI
Authors: Hyungkyu Huh, Menhel Kinno, Alex Barker, Michael Markl, James D Thomas
Journal: Circulation (2018)

Introduction: Accurate measurement of the EOA for the evaluation of aortic stenosis requires precise computation of the LVOT stroke volume (LVOTsv). In this study, we systematically investigated as...
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
Authors: Chenhe Yi, Lirong Chen, Zhifei Lin, Lu Liu, Weiqing Shao, Rui Zhang, Jing Lin, Jubo Zhang, Wenwei Zhu, Huliang Jia, Lunxiu Qin, Lu Lu, Jinhong Chen
Journal: Hepatology (2021)

Background and Aims Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have displayed an impressive objective response rate. This study aimed to clarify the mechanism for optimal patient selection. Approach and Results First, in patients with HCC, lenvatinib‐treated recurrent tumors had lower programmed death ligand 1 (PD‐L1) expression and regulatory T cell (Treg) infiltration compared with matched primary tumors. Consistently, in C57BL/6 wild‐type mice receiving anti–programmed cell death 1 (PD‐1) therapy, PD‐L1 expression and Treg infiltration in s.c. tumors were reduced when adding lenvatinib to the scheme. Mechanistically, on the one hand, FGF receptor 4 (FGFR4) was the most pivotal target in PD‐L1 down‐regulation by lenvatinib in vitro . Furthermore, lenvatinib reinforced the proteasomal degradation of PD‐L1 by blocking the FGFR4–glycogen synthase kinase 3β axis and rescued the sensitivity of interferon‐γ‐pretreated HCC cells to T‐cell killing by targeting FGFR4. On the other hand, the level of IL‐2 increased after anti‐PD‐1 treatment, but IL‐2‐mediated Treg differentiation was blocked by lenvatinib through targeting FGFR4 to restrain signal transducer and activator of transcription 5 (STAT5) phosphorylation. By regulating the variations in the number of Tregs and the tumor FGFR4 level in C57BL/6–forkhead box protein P3 ( Foxp3DTR ) mice, we found that high levels of FGFR4 and Treg infiltration sensitized tumors to the combination treatment. Finally, high levels of FGFR4 and Foxp3 conferred immune tolerance but better response to the combined therapy in patient cohorts. Conclusions Lenvatinib reduced tumor PD‐L1 level and Treg differentiation to improve anti‐PD‐1 efficacy by blocking FGFR4. Levels of FGFR4 expression and Treg infiltration in tumor could serve as biomarkers for screening patients with HCC using lenvatinib plus anti‐PD‐1 combination therapy.